Merck-Moderna cancer vaccine cuts melanoma recurrence or death risk by 42%
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Merck and Moderna’s personalized mRNA vaccine intismeran, combined with Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a pivotal trial. Specialists are now considering its adoption and potential use against other tumors.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu